- Raw materials
- Respiratory Tract Agents
- Reproterol
Reproterol API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Reproterol | CAS No: 54063-54-6 | GMP-certified suppliers
A medication that provides bronchodilation for improved airflow in obstructive airway diseases, primarily studied for exercise-induced asthma treatment.
Therapeutic categories
Product Snapshot
- Reproterol is formulated as a metered-dose aerosol for inhalation
- It is primarily developed for respiratory indications
- The product is currently in the investigational stage and not yet approved by major regulatory authorities
Clinical Overview
Pharmacologically, reproterol acts as a selective beta-2 adrenergic receptor agonist. This mechanism induces relaxation of bronchial smooth muscle by stimulating beta-2 adrenergic receptors, leading to bronchodilation and improved airflow in obstructive airway diseases. Despite its classification among adrenergic agents and bronchodilators, specific pharmacodynamic parameters and detailed mechanisms of action have not been fully characterized in the public domain.
Regarding absorption, distribution, metabolism, and excretion (ADME), detailed clinical pharmacokinetic data for reproterol are currently limited. As a compound structurally related to other beta-2 agonists and xanthines, it is anticipated to undergo hepatic metabolism, with elimination routes potentially including renal excretion of metabolites. However, definitive ADME profiles require further clinical investigation.
Safety and toxicity considerations for reproterol remain to be comprehensively established due to its investigational status. Agents in the beta-2 agonist class are generally associated with potential cardiovascular effects such as tachycardia and hypertension, consistent with the compound’s categorization among agents producing these effects. Monitoring for similar safety signals would be prudent in clinical evaluations.
Reproterol is not currently approved for clinical use; thus, no marketed pharmaceutical products or brand names are authorized internationally at this time. Its investigational role is confined to controlled clinical trials, particularly exploring asthma-related indications.
For formulation scientists and API sourcing professionals, attention should be given to the chemical purity and stability of reproterol. Procurement should ensure compliance with relevant pharmacopeial standards or guidelines applicable to investigational compounds. Robust characterization, including polymorphic form, residual solvent content, and impurity profile, is critical for quality assurance in API manufacturing and regulatory documentation.
Identification & chemistry
| Generic name | Reproterol |
|---|---|
| Molecule type | Small molecule |
| CAS | 54063-54-6 |
| UNII | 11941YC6RN |
| DrugBank ID | DB12846 |
Formulation & handling
- Reproterol is a small molecule xanthine derivative intended primarily for inhalation via aerosol.
- Water solubility is moderate, facilitating formulation in metered-dose inhalers for respiratory delivery.
- Stability considerations should include protection from moisture and potential degradation in aqueous media.
Regulatory status
Reproterol is a type of Respiratory Tract Agents
Respiratory Tract Agents are a vital category of pharmaceutical APIs (Active Pharmaceutical Ingredients) designed to treat respiratory conditions and diseases. These agents are specifically formulated to target the respiratory system, which includes the lungs, airways, and nasal passages. They play a crucial role in managing various respiratory disorders, such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis.
Respiratory Tract Agents encompass a wide range of medications, including bronchodilators, corticosteroids, antihistamines, and mucolytics. Bronchodilators are commonly used to relieve airway constriction and facilitate smooth breathing by relaxing the muscles in the airways. Corticosteroids help reduce inflammation in the respiratory system, alleviating symptoms and preventing exacerbations. Antihistamines work by blocking histamine receptors, thus mitigating allergic reactions that often impact the respiratory tract. Mucolytics aid in loosening and thinning mucus, making it easier to expel from the airways.
These APIs are developed through rigorous research and development processes, ensuring their efficacy, safety, and compliance with regulatory standards. Pharmaceutical manufacturers rely on advanced technologies and stringent quality control measures to produce high-quality Respiratory Tract Agents. These APIs are subsequently incorporated into various dosage forms, including inhalers, nasal sprays, nebulizers, and oral medications.
Respiratory Tract Agents are essential in the management of respiratory conditions, providing relief from symptoms, improving lung function, and enhancing the overall quality of life for patients. They are prescribed by healthcare professionals and often used in combination therapies to achieve optimal results. As respiratory disorders continue to affect a significant portion of the global population, the development and availability of effective Respiratory Tract Agents play a vital role in addressing these health challenges and improving patient outcomes.
